Compare Futu Holdings Ltd (FUTU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Futu Holdings Ltd trades at $107.38 (market cap $15.35B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Futu Holdings Ltd is far larger — about 15.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Futu Holdings Ltd pays a 2.37% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FUTU | MRVI | |
|---|---|---|
Market Cap | $15.35B | $977.37M |
Volume | 1,329,666 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $199.04 | $9.00 |
52-Week Low | $89.76 | $2.83 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $15.69B | $1.08B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $114.06, up 1.6% today, with a neutral technical signal and bullish moving averages. Revenue surged to $22.85 billion in 2025, with a net income margin of 49.62%, while valuation ratios like a P/E of 11.38 appear attractive. Recent news highlights Moomoo's expansion and a class action lawsuit deadline.
The outlook is mixed: strong fundamentals and analyst upside targets near 33% support growth, but legal risks and a recent earnings miss pose headwinds. Investors should weigh robust profitability against regulatory and competitive pressures in the financial services sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
